Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 10/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069774 | 0.93 | KDM4E (0.46) | CYP2C19RETKDM4ETP53SMN1; SMN2 | |
| SCHEMBL20069795 | 0.93 | CYP2C19 (0.40) | CYP2C19RETKDM4ECYP2D6POLB | |
| SCHEMBL20069776 | 0.93 | CYP2C19 (0.40) | CYP2C19RETKDM4ECYP2D6POLB | |
| SCHEMBL20205850 | 0.92 | CYP2C19 (0.41) | CYP2C19RETKDM4ETP53SMN1; SMN2 | |
| SCHEMBL20069782 | 0.89 | RET (0.42) | CYP2C19RETSMN1; SMN2 | |
| SCHEMBL20069804 | 0.87 | RET (0.42) | CYP2C19RETKDM4ETP53SMN1; SMN2 | |
| SCHEMBL20070269 | 0.86 | RET (0.46) | CYP2C19RETKDM4ESMN1; SMN2 | |
| SCHEMBL20069790 | 0.85 | RET (0.43) | CYP2C19RETKDM4ECYP2D6 | |
| SCHEMBL20069765 | 0.83 | CYP2C19 (0.44) | CYP2C19RETKDM4ETP53SMN1; SMN2 | |
| SCHEMBL20069482 | 0.83 | RET (0.45) | CYP2C19RETSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| WO-2018071454-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | CYP2C19 4137/4885RET 1/4885KDM4E 547/4885 |
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | CYP2C19 4137/4885RET 1/4885KDM4E 547/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CYP2C19 4137/4885RET 1/4885KDM4E 547/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CYP2C19 4137/4885RET 1/4885KDM4E 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.